ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,745.37
      0.40%
      US Tech 100
      19,602.40
      0.12%
      Dow Jones
      42,175.11
      0.00%
      Brent Oil
      70.93
      -0.03%
      Bitcoin
      65,461.47
      0.43%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Canada
      5. CSE
      6. Caprock Mining Corp (CAPR)

      7. Caprock Mining Corp (CAPR) News

      CAPR

      Caprock Mining (CAPR)

      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CAPR
      DateTimeSourceHeadlineSymbolCompany
      09/24/20244:03PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
      09/24/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
      09/24/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
      09/24/20248:00AMGlobeNewswire Inc.Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyNASDAQ:CAPRCapricor Therapeutics Inc
      09/23/20249:25AMGlobeNewswire Inc.Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024NASDAQ:CAPRCapricor Therapeutics Inc
      09/17/20249:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
      09/17/20249:15AMGlobeNewswire Inc.Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
      09/06/20248:30AMGlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
      08/23/20244:02PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
      08/23/20244:01PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CAPRCapricor Therapeutics Inc
      08/09/20249:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
      08/08/20245:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
      08/07/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
      08/07/20244:05PMGlobeNewswire Inc.Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
      07/31/20249:00AMGlobeNewswire Inc.Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7NASDAQ:CAPRCapricor Therapeutics Inc
      07/01/20249:00AMGlobeNewswire Inc.Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® IndexesNASDAQ:CAPRCapricor Therapeutics Inc
      06/28/20249:00AMGlobeNewswire Inc.Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
      06/25/202410:30AMGlobeNewswire Inc.CORRECTION: Capricor TherapeuticsNASDAQ:CAPRCapricor Therapeutics Inc
      06/25/20248:30AMGlobeNewswire Inc.Capricor Therapeutics Announces for the Treatment of Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
      06/14/20244:31PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
      06/11/20249:25AMGlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA PathwayNASDAQ:CAPRCapricor Therapeutics Inc
      06/04/20249:00AMGlobeNewswire Inc.Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
      05/15/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
      05/15/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
      05/14/20249:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
      05/13/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
      05/13/20244:05PMGlobeNewswire Inc.Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
      05/09/20249:15AMGlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
      05/08/20249:00AMGlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
      05/06/20249:00AMGlobeNewswire Inc.Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13NASDAQ:CAPRCapricor Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CAPR